Tags

Type your tag names separated by a space and hit enter

Amantadine reduces the duration of levodopa-induced dyskinesia: a randomized, double-blind, placebo-controlled study.
Parkinsonism Relat Disord. 2005 Nov; 11(7):449-52.PR

Abstract

We evaluated the effects of amantadine on levodopa-induced dyskinesia (LID) in eighteen consecutive Parkinson's disease (PD) patients in a randomized, double-blind, placebo-controlled study. The primary outcomes were the Clinical Dyskinesia Rating Scale (CDRS) and the Unified Parkinson's Disease Rating Scale (UPDRS) part IVa score changes. The secondary outcomes were the UPDRS II and III score changes. Amantadine did not change the CDRS score for hyperkinesia or dystonia, but decreased the duration of LID and its influence on daily activities (p=0.04) and the UPDRS II score (p=0.01) more than placebo. These findings show that amantadine reduces the duration of LID and improves motor disability in PD.

Authors+Show Affiliations

Department of Clinical Medicine, Federal University of Ceará, Rua Prof. Costa Mendes 1608 4 Andar, CEP 60430 040, Fortaleza, Ceará, Brazil.No affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

16154788

Citation

da Silva-Júnior, Francisco Pereira, et al. "Amantadine Reduces the Duration of Levodopa-induced Dyskinesia: a Randomized, Double-blind, Placebo-controlled Study." Parkinsonism & Related Disorders, vol. 11, no. 7, 2005, pp. 449-52.
da Silva-Júnior FP, Braga-Neto P, Sueli Monte F, et al. Amantadine reduces the duration of levodopa-induced dyskinesia: a randomized, double-blind, placebo-controlled study. Parkinsonism Relat Disord. 2005;11(7):449-52.
da Silva-Júnior, F. P., Braga-Neto, P., Sueli Monte, F., & de Bruin, V. M. (2005). Amantadine reduces the duration of levodopa-induced dyskinesia: a randomized, double-blind, placebo-controlled study. Parkinsonism & Related Disorders, 11(7), 449-52.
da Silva-Júnior FP, et al. Amantadine Reduces the Duration of Levodopa-induced Dyskinesia: a Randomized, Double-blind, Placebo-controlled Study. Parkinsonism Relat Disord. 2005;11(7):449-52. PubMed PMID: 16154788.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Amantadine reduces the duration of levodopa-induced dyskinesia: a randomized, double-blind, placebo-controlled study. AU - da Silva-Júnior,Francisco Pereira, AU - Braga-Neto,Pedro, AU - Sueli Monte,Francisca, AU - de Bruin,Veralice Meireles Sales, Y1 - 2005/09/09/ PY - 2005/03/04/received PY - 2005/05/12/revised PY - 2005/05/16/accepted PY - 2005/9/13/pubmed PY - 2006/1/18/medline PY - 2005/9/13/entrez SP - 449 EP - 52 JF - Parkinsonism & related disorders JO - Parkinsonism Relat Disord VL - 11 IS - 7 N2 - We evaluated the effects of amantadine on levodopa-induced dyskinesia (LID) in eighteen consecutive Parkinson's disease (PD) patients in a randomized, double-blind, placebo-controlled study. The primary outcomes were the Clinical Dyskinesia Rating Scale (CDRS) and the Unified Parkinson's Disease Rating Scale (UPDRS) part IVa score changes. The secondary outcomes were the UPDRS II and III score changes. Amantadine did not change the CDRS score for hyperkinesia or dystonia, but decreased the duration of LID and its influence on daily activities (p=0.04) and the UPDRS II score (p=0.01) more than placebo. These findings show that amantadine reduces the duration of LID and improves motor disability in PD. SN - 1353-8020 UR - https://www.unboundmedicine.com/medline/citation/16154788/Amantadine_reduces_the_duration_of_levodopa_induced_dyskinesia:_a_randomized_double_blind_placebo_controlled_study_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S1353-8020(05)00099-4 DB - PRIME DP - Unbound Medicine ER -